The Board of Directors of Cipla Limited convened a meeting on May 13, 2026, commencing at 9:45 a.m. (IST) and concluding at 1:00 p.m. (IST), to discuss several strategic proposals. In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board approved the convening of the company's 90th Annual General Meeting (AGM). The meeting is scheduled to take place on Thursday, June 25, 2026.

Stock Options and ESARs Granted

The Board approved the grant of stock options and Employee Stock Appreciation Rights (ESARs) to eligible employees under the Cipla Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021. The details of the grants, including the number of options and vesting periods, are outlined below.

The exercise price for the stock options is INR 2 per stock option, while the exercise price for the ESARs is INR 2 per equity share.

Cost Auditor Appointment

M/s Joshi Apte & Associates, Cost Accountants (Firm Registration no. 000240), were appointed as the Cost Auditors of the company for the financial year 2026-27. The firm was established by experienced professionals and offers services in the domain of Cost and Management Accounting. Its core strength lies in a team that blends seasoned experts with dynamic young professionals, enabling delivery of services with a high level of professionalism. The appointment is subject to the relevant regulations and the SEBI Master Circular.

Senior Management Appointment

The Board approved the appointment of Mr. Sushrut Kulkarni as President & Global Chief – Integrated Product Development (IPD), effective May 18, 2026. He will also serve as a member of the Management Council and Senior Management Personnel. The key details of his appointment are summarised below.

Mr. Kulkarni brings over three decades of experience in the pharmaceutical industry. Prior to joining Cipla, he served as Global Head – Integrated Product Development Organization (IPDO) and a member of the Management Council at Dr. Reddy's Laboratories. Over the course of his career, he has held senior leadership roles at Glenmark and Zydus Lifesciences, and earlier positions of responsibility at Torrent Research Centre, Sandoz India, and Rhone Poulen (India) Limited. He holds a Bachelor's and Master's degree in Pharmacy from Shivaji University and the University of Mumbai, respectively. He has a strong track record of multiple filings and approvals across regulated and semi-regulated markets across diverse dosage forms.

Cipla has flagged growing operational challenges as geopolitical tensions in the Middle East continue to weigh on freight costs and supply chain dynamics. A company executive stated that as the Iran crisis prolongs, some cost escalations are beginning to seep into the system, signaling a potential shift in the company's ability to fully absorb these pressures going forward.

Freight and Supply Chain Challenges in Focus

The executive acknowledged that Cipla has been facing challenges on the freight and supply front specifically related to the Middle East region. The company has so far relied on inventory management as a key mechanism to cushion the impact of elevated freight costs and supply disruptions into the region.

Prolonged Crisis Straining Cost Buffers

While inventory management has provided a temporary buffer, the executive's remarks suggest that the sustainability of this approach is under pressure. As the Iran crisis extends, the company indicated that cost escalations are increasingly difficult to contain entirely, pointing to a gradual erosion of the cushioning effect that inventory strategies have provided thus far.

The development highlights the broader impact of regional geopolitical instability on pharmaceutical supply chains, particularly for companies with exposure to Middle Eastern markets. Cipla's management commentary underscores the need to monitor freight cost trends and supply availability as the situation evolves.